ClinVar Miner

Submissions for variant NM_001079866.2(BCS1L):c.871C>T (p.Arg291Ter)

gnomAD frequency: 0.00005  dbSNP: rs201454788
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000195977 SCV000251195 pathogenic not provided 2017-11-13 criteria provided, single submitter clinical testing The R291X variant in the BCS1L gene has been reported in an individual with Bjornstad syndrome who also harbors the Q302E variant in trans (Hinson et al., 2007). Functional studies demonstrate that the R291X variant results in mitochondrial dysfunction and reduced electron-transport chain activity (Hinson et al., 2007). This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The R291X variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016). We interpret R291X as a pathogenic variant.
Illumina Laboratory Services,Illumina RCV000368540 SCV000427447 uncertain significance BCS1L-Related Disorders 2017-04-27 criteria provided, single submitter clinical testing The BCS1L c.871C>T (p.Arg291Ter) variant is a stop-gained variant. The p.Arg291Ter variant has been reported in one study in which it is found in a compound heterozygous state with a missense variant in one individual with Bjornstad syndrome (Hinson et al. 2007). The p.Arg291Ter variant was absent from 300 control chromosomes and is reported at a frequency of 0.00008 in the European (non-Finnish) population of the Exome Aggregation Consortium. Functional complementation studies in yeast showed that the variant failed to support growth on media that require respiratory-chain metabolism (Hinson et al. 2007). The amount of superoxide produced by complex III activity was reduced by 61% in mitochondria in individuals with Bjornstad syndrome while complex I-dependent production of reactive oxygen species was increased by 30%. Due to the potential impact of stop-gained variants and the supporting evidence, this variant is classified as a variant of unknown significance but suspicious for pathogenicity for BCS1L-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000586158 SCV000698305 likely pathogenic Pili torti-deafness syndrome 2021-08-20 criteria provided, single submitter clinical testing Variant summary: BCS1L c.871C>T (p.Arg291X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 2e-05 in 250748 control chromosomes (gnomAD). c.871C>T has been reported in the literature in a compound heterozygote individual affected with Bjornstad syndrome (Hinson_2007). The authors of this study also reported experimental evidence evaluating an impact on protein function, demonstrating in a yeast complementation assay that the mutant protein failed to rescue growth on a medium that requires an active respiratory-chain. They also showed decreased electron-transport activities with increased production of reactive oxygen species in lymphocytes acquired from patients with Bjornstad syndrome and complex III deficiency (however, no patient specific data were provided, Hinson_2007). Four ClinVar submitters (evaluation after 2014) cite the variant as uncertain significance (n=1), likely pathogenic (n=1) and pathogenic (n=2). Based on the evidence outlined above, the variant was classified as likely pathogenic.
Counsyl RCV000675151 SCV000800755 likely pathogenic GRACILE syndrome 2017-04-11 criteria provided, single submitter clinical testing
Baylor Genetics RCV000675151 SCV001162936 pathogenic GRACILE syndrome criteria provided, single submitter clinical testing
Invitae RCV000195977 SCV001231785 pathogenic not provided 2021-09-25 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Arg291*) in the BCS1L gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BCS1L are known to be pathogenic (PMID: 12215968, 17314340, 19162478, 19508421, 22277166, 25895478). This variant is present in population databases (rs201454788, ExAC 0.01%). This premature translational stop signal has been observed in individual(s) with Bjornstad syndrome (PMID: 17314340). ClinVar contains an entry for this variant (Variation ID: 214162). For these reasons, this variant has been classified as Pathogenic.
Molecular Genetics, Royal Melbourne Hospital RCV000586158 SCV002503731 pathogenic Pili torti-deafness syndrome 2022-04-22 criteria provided, single submitter clinical testing This sequence change creates a premature termination codon at position 291 in exon 7 (of 9) of BCS1L, p.(Arg291*). It is expected to result in an absent or disrupted protein product in a gene where loss of function is an established mechanism of disease. The variant is present in a large population cohort at a frequency of 0.003%, which is consistent with a recessive condition (rs201454788, 8/282,138 alleles, 0 homozygotes in gnomAD v2.1). The variant has been identified compound heterozygous with a second allele in a case diagnosed with Bjornstad syndrome (PMID: 17314340). Additionally, the variant demonstrates attenuated growth in a yeast complementation assay (PMID: 17314340). Based on the classification scheme RMH ACMG Guidelines v1.2.1, this variant is classified as PATHOGENIC . Following criteria are met: PVS1, PM2, PS3_Supporting.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.